Drug intelligence / Profile preview

RHA 4 + lidocaine

Development stage
Unknown
Lead developer
Teoxane
Modality
Small Molecules
Administration
Subcutaneous, Intradermal
01

Overview

RHA 4 + lidocaine is an **injectable dermal filler** composed of **cross-linked hyaluronic acid** combined with **lidocaine** as a local anesthetic[2][3][4][5][7]. Its primary use is for the **correction of moderate to severe dynamic facial wrinkles and folds**, such as nasolabial folds, cheek augmentation, and restoration of facial volume in adults. The hyaluronic acid in RHA 4 is both modified and non-modified to mimic the behavior and elasticity of native hyaluronic acid found in the skin, improving volume while maintaining natural movement and softness. Lidocaine is included to reduce discomfort during injection. The filler is biodegradable and is administered into the deep dermis or superficial subcutaneous tissue. **Teoxane** developed and manufactures this product, often in collaboration or distribution partnership with companies like **Revance** for the U.S. market[2][3][6][7]. The product is FDA approved for specific aesthetic indications in adults[7].

Brand names
RHA 4 with lidocaineRHA4 with lidocaineRHA-4 with lidocaineTeosyal RHA 4 Lidocaine
Other names
Teosyal RHA 4 Lidocaine
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on RHA 4 + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RHA 4 + lidocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call